Parathyroid cancer screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
* Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings. | |||
==Screening== | ==Screening== | ||
* Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings. | * Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings. | ||
Latest revision as of 15:11, 29 December 2015
|
Parathyroid cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parathyroid cancer screening On the Web |
|
American Roentgen Ray Society Images of Parathyroid cancer screening |
|
Risk calculators and risk factors for Parathyroid cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
- Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.
Screening
- Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.